CHANGES IN THE IMMUNE STATUS OF PATIENTS WITH METASTATIC SOLID TUMORS DURING STEREOTACTIC RADIATION THERAPY
##article.numberofdownloads## 33
##article.numberofviews## 295
PDF (Русский)

Keywords

METASTATIC TUMOR PROCESS
STEREOTACTIC BODY RADIATION THERAPY (SBRT)
IMMUNOTHERAPY
IMMUNE STATUS
ACTIVATION OF T-LYMPHOCYTES

How to Cite

Zozulya, A., Novikov, S., Baldueva, I., Girdyuk, D., Yemelyanova, N., Tyuryaeva, Y., Fedosova, E., Antipov, F., Navoloka, A., Kanaev, S., & Belyaev, A. (2020). CHANGES IN THE IMMUNE STATUS OF PATIENTS WITH METASTATIC SOLID TUMORS DURING STEREOTACTIC RADIATION THERAPY. Voprosy Onkologii, 66(3), 277–282. https://doi.org/10.37469/0507-3758-2020-66-3-277-282

Abstract

Purpose. To evaluate immunological status in patients with metastatic forms of solid tumors before and at different intervals after stereotactic body radiation therapy (SBRT) of metastatic lesions. Materials and methods. A quantitative assessment and analysis of blood immunological parameters was conducted before irradiation, after 3-4 weeks and 6-8 weeks after SBRT in patients with malignant tumors with oligometastases in the liver and lungs. All peripheral blood samples were analyzed by flow cytometry. Statistical analysis was performed using Friedman and Nemenyi criteria. Results. 3-4 weeks after the end of SBRT, we observed statistically significant increase of T-lymphocytes (CD3+CD19-); T-helpers (CD3+CD4+); activated T-helpers (CD3+CD4+HLA-DR+); activated cytotoxic T-lymphocytes (CD3+CD8+HLA-DR+) and decrease of B-lymphocytes (CD3-CD19+). Subsequently, after 6-8 weeks after the end of irradiation we detected decrease of T-lymphocytes (CD3+CD19-) and continuing increase in activated T-helpers (CD3+CD4+HLA-DR+) and activated cytotoxic T-lymphocytes (CD3+CD8+HLA-DR+). Conclusion. Thus, revealed dynamics of immunological parameters indicates the induction of the T-cell link of antitumor immunity against decreasing of indicators of humoral immunity.

https://doi.org/10.37469/0507-3758-2020-66-3-277-282
##article.numberofdownloads## 33
##article.numberofviews## 295
PDF (Русский)

References

Yamada Y Cancer Rehabilitation: Principles and Practice. - New York, NY: Demos Medical Publishing, 2009.

Рагулин Ю.А. Сочетание иммунотерапии и лучевой терапии при немелкоклеточном раке легкого // Онкология. Журнал им. П.А. Герцена. - 2018. - Т. 7(5). - С. 90-96. - DOI: 10.17116/onkolog2018705190

Amaravadi R.K., Thompson C.B. The roles of therapy-induced autophagy and necrosis in cancer treatment // Clin Cancer Res. - 2007. - Vol. 13. - P. 7271-7279. -. DOI: 10.1158/1078-0432.CCR-07-1595

Литтл Д.Б. Немишенные эффекты ионизирующих излучений: выводы применительно к низкодозовым воздействиям // Радиац. биология. Радиоэкология. - 2007. - Т 47. - № 3. - С. 262-272.

Mothersill C. Relevance of radiation induced bystander effects for environmental risk assessment // Радиац. биология. Радиоэкология. - 2002. - Т. 42. - № 6. - С. 586-587.

Golden E.B., Frances D., Pellicciotta I. et al. Radiation fosters dose-dependent and chemotherapy-induced immunogenic cell death // Oncoimmunology. - 2014. - Vol. 3. - e28518. -. DOI: 10.4161/onci.28518

Hanna G.G., Illidge T. Radiotherapy and immunotherapy combinations in non-small cell lung cancer: a promising future? // Clin Oncol. - 2016. - Vol. 28(11). - P. 726731. -https://doi.org/10.1016Zj.clon.2016.07.014.

Matsumura S., Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation // Radiat Res. - 2010. -Vol. 173(4). - P 418-425. - DOI: 10.1667/rr1860.1

Kwilas A.R. In the field: exploiting the untapped potential of immunogenic modulation by radiation in combination with immunotherapy for the treatment of cancer // Front Oncol. - 2012. - Vol. 2. - P 104. - DOI: 10.3389/fonc.2012.00104

Балдуева И.А., Зозуля А.Ю., Новиков С.Н. Стереотаксическая лучевая терапия в фокусе системных иммунологических эффектов // Злокачественные опухоли. - 2019. - Т. 9(3s1). - С. 23-25. - DOI: 10.18027/2224-5057-2019-9-3s1-23-25

Friedman Milton. A comparison of alternative tests of significance for the problem of m rankings // The Annals of Mathematical Statistics. 1940. - Vol. 11 (1). - P. 86-92.

Nemenyi P. Distribution-free Multiple Comparisons. - Ph.D. thesis, Princeton University, 1963.

Demaria S., Ng B., Devitt M.L. et al. Ionizing radiation inhibition of distant untreated tumors (abscopal effect) is immune mediated // Int. J. Radiat. Oncol. Biol. Phys. - 2004. - Vol. 58. - P. 862-870.

Zhang H., Liu L., Yu D. et al. An in situ autologous tumor vaccination with combined radiation therapy and TLR9 agonist therapy // PLoS ONE. - 2012. - Vol. 7(5). - P. e38111.

Gupta A., Probst H.C., Vuong V. et al. Radiotherapy promotes tumor-specific effector CD8+ T cells via dendritic cell activation // J. Immunol. - 2012. - Vol. 189. - P 558-566.

Lee Y, Auh S.L., Wang YG. et al. Therapeutic effects of ablative radiation on local tumor require CD8+ T cells: changing strategies for cancer treatment // Blood. - 2009. - Vol. 114. - P. 589-595.

Zheng Y, Shi A., Wang W. et al. Post-treatment immune parameters predict cancer control and pneumonitis in stage I non-small-cell lung cancer patients treated with stereotactic ablative radiotherapy // Clinical Lung Cancer. - 2018. - DOI: 10.1016/j.cllc.2017.12.012

Theelen W., Peulen H., Lalezari F. et al. Randomized phase II study of pembrolizumab after stereotactic body radiotherapy (SBRT) versus pembrolizumab alone in patients with advanced non-small cell lung cancer: the PEMBRO-RT study // J Clin Oncol. - 2018. - Vol. 36. - P. 9023.

Turajlic S., Litchfield K., Xu H. et al. Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis // Lancet Oncol. -2017. - Vol. 18(8). - P.1009-1021

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

© АННМО «Вопросы онкологии», Copyright (c) 2020